DOCS Form 4: Director awarded 3,221 RSUs, now owns 19,839 shares
Rhea-AI Filing Summary
Benjamin Regina M., a director of Doximity, Inc. (DOCS), received a grant of 3,221 restricted stock units (RSUs) on 08/28/2025 under the issuer's non-employee director compensation policy. Each RSU represents a contingent right to one share of Class A common stock and the grant was reported with a transaction price of $0. The RSUs vest in full on the earlier of the first anniversary of the grant date or the issuer's next annual meeting of stockholders, subject to the reporting person's continued service as a director through the applicable vesting date. After the grant, the reporting person beneficially owned 19,839 shares of Class A common stock on a direct basis. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/02/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine director compensation grant with near-term vesting ties pay to continued board service.
This RSU award to a non-employee director follows standard corporate practice of using equity to align outside directors with shareholder interests. The vesting schedule — full vesting at the earlier of one year or the next annual meeting — creates a clear service condition rather than performance contingencies. The report shows direct beneficial ownership of 19,839 Class A shares after the grant, which updates insider holdings transparency. There are no disclosed special acceleration provisions or cash purchase, and the transaction was reported under Form 4 rules.
TL;DR: Non-material equity grant from an investor-impact perspective; standard disclosure of insider holdings.
The Form 4 documents a grant of 3,221 RSUs at $0 per unit to a director, increasing reported direct beneficial ownership to 19,839 Class A shares. For investors, this is a routine compensation disclosure rather than a corporate event expected to materially affect valuation or operations. The filing provides clear vesting terms and the grant date, satisfying Section 16 reporting requirements. No derivative positions, exercises, or sales are reported.